US8772478, 15::US8772478, 8

ID: ALA3643914

Chembl Id: CHEMBL3643914

PubChem CID: 49854511

Max Phase: Preclinical

Molecular Formula: C25H30N4O5S

Molecular Weight: 498.61

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cc(COc2ccc(S(=O)(=O)NC[C@@H](C(=O)NO)N3CCCCC3)cc2)c2ccccc2n1

Standard InChI:  InChI=1S/C25H30N4O5S/c1-18-15-19(22-7-3-4-8-23(22)27-18)17-34-20-9-11-21(12-10-20)35(32,33)26-16-24(25(30)28-31)29-13-5-2-6-14-29/h3-4,7-12,15,24,26,31H,2,5-6,13-14,16-17H2,1H3,(H,28,30)/t24-/m0/s1

Standard InChI Key:  XYPVMSYCSIAWKF-DEOSSOPVSA-N

Associated Targets(Human)

MMP1 Tchem Matrix metalloproteinase-1 (7046 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MMP9 Tchem Matrix metalloproteinase 9 (6779 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MMP3 Tchem Matrix metalloproteinase 3 (3433 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADAM33 Tchem Disintegrin and metalloproteinase domain-containing protein 33 (14 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADAM9 Tchem ADAM9 (81 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADAM10 Tchem ADAM10 (375 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADAM17 Tchem ADAM17 (3550 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hepatocyte (2737 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TK6 (138 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 498.61Molecular Weight (Monoisotopic): 498.1937AlogP: 2.76#Rotatable Bonds: 9
Polar Surface Area: 120.86Molecular Species: NEUTRALHBA: 7HBD: 3
#RO5 Violations: HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 8.70CX Basic pKa: 5.66CX LogP: 2.41CX LogD: 2.38
Aromatic Rings: 3Heavy Atoms: 35QED Weighted: 0.31Np Likeness Score: -1.32

References

1.  (2014)  Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics, 
2. Boiteau JG, Ouvry G, Arlabosse JM, Astri S, Beillard A, Bhurruth-Alcor Y, Bonnary L, Bouix-Peter C, Bouquet K, Bourotte M, Cardinaud I, Comino C, Deprez B, Duvert D, Féret A, Hacini-Rachinel F, Harris CS, Luzy AP, Mathieu A, Millois C, Orsini N, Pascau J, Pinto A, Piwnica D, Polge G, Reitz A, Reversé K, Rodeville N, Rossio P, Spiesse D, Tabet S, Taquet N, Tomas L, Vial E, Hennequin LF..  (2018)  Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.,  26  (4): [PMID:28818461] [10.1016/j.bmc.2017.07.054]